skip to Main Content

All Press Releases

Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase

Malmö, October 11, 2022 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety study in rats has completed the in-life phase with no adverse signals during the dosing phase.  Outstanding investigations still to be completed include the pathology, and the bioanalysis and toxicokinetic analyses which are necessary to determine the…

Read more

Pila Pharma delårsrapport för 1 april – 30 juni 2022

Malmö, 26 augusti 2022 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets delårsrapport för perioden april – juni 2022 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information SAMMANFATTNING AV DELÅRSRAPPORT Andra kvartalet (1 april–30 juni 2022) Rörelsens intäkter uppgick till 651 kSEK (0)Rörelseresultatet (EBIT) uppgick till - 2 250 kSEK (-…

Read more

Pila Pharma publishes interim report April 1 – June 30, 2022

Malmö, August 26, 2022 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period April – June 2022. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information SUMMARY OF YEAR-END REPORT Second quarter (April 1 – June 30, 2022) Revenue was SEK  651 kSEK (0)Operating loss (EBIT) was…

Read more

Contact us

FÅ PRESSMEDDELANDEN
GET PRESS RELEASES

Back To Top
Search